Last reviewed · How we verify
NCT06788652
A Study of Patients With Relapsed/Refractory Mantle Cell Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting
trial testing Lisocabtagene maraleucel in Mantle Cell Lymphoma (MCL) in 300 participants. Currently enrolling.
30 September 2044
Quick facts
| Lead sponsor | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 300 |
| Start date | 4 February 2025 |
| Primary completion | 30 September 2044 |
| Estimated completion | 30 September 2044 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Lisocabtagene maraleucel (LISOCABTAGENE MARALEUCEL) — full drug profile →
Conditions studied
- Mantle Cell Lymphoma (MCL) — all drugs for Mantle Cell Lymphoma (MCL) →
Sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company — full company profile →
Who can join
18 and older, any sex, with Mantle Cell Lymphoma (MCL). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to understand the long-term safety and effectiveness of lisocabtagene maraleucel (liso-cel) for the treatment of Mantle Cell Lymphoma (MCL).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06788652
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Lisocabtagene maraleucel
Trials testing the same drug.
- NCT06794268 — A Study to Patients With Relapsed/Refractory Follicular Lymphoma Treated With Liso-cel (Lisocabtagene Maraleucel) in the · recruiting
- NCT06788639 — A Study of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated With Lisoca · recruiting
- NCT06357754 — Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Mod · recruiting
Other recruiting trials for Mantle Cell Lymphoma (MCL)
Currently open trials in the same condition.
- NCT07077512 — Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell Lymphoma · Phase 2 · recruiting
- NCT07272499 — Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease · Phase 2 · recruiting
- NCT07257510 — Pomalidomide Plus Orelabrutinib and Zuberitamab in Untreated Mantle Cell Lymphoma · NA · recruiting
- NCT07199296 — Orelabrutinib and Rituximab With Optional Autologous Hematopoietic Stem Cell Transplantation in MCL Treatment · Phase 2 · recruiting
- NCT06846489 — Acalabrutinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate-Risk Younger Untreated Mantle Cell Lym · Phase 2 · recruiting
Other Juno Therapeutics, Inc., a Bristol-Myers Squibb Company trials
Trials by the same sponsor.
- NCT07335562 — A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versu · Phase 3 · recruiting
- NCT07015242 — A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplan · Phase 2 · recruiting
- NCT07115745 — A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Disease · Phase 1 · recruiting
- NCT07015983 — A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite I · Phase 2 · recruiting
- NCT06615479 — A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or · Phase 3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06788652 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
- Last refreshed: 24 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06788652.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing